常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.81/-7.44
|
|
企業價值
34.60M
|
| 資產負債 |
|
每股賬面淨值
2.82
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
299.06K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitiveconditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing. |

4.4847 
